TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06647303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training on communication framework
Description: Surgeons will receive training on the Better Conversations framework

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Participants will attend a focus group to discuss the survey instruments used in this study which will help with future study design

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys
Description: Participants will complete surveys regarding the surgeon's communication skills
Study: NCT06475703

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Isla wound prioritisation module
Description: The intervention group will use the artificial intelligence enabled platform with the new wound prioritisation module for 30 days after surgery in addition to standard post-operative wound follow-up care for 60 days after surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard follow-up
Description: Standard care, mapped during the economic scoping exercise may include; out-patient appointments, advised to contact GP, or no follow-up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard follow-up
Description: Standard care, mapped during the economic scoping exercise may include; out-patient appointments, advised to contact GP, or no follow-up.
Study: NCT06485297

Intervention type: OTHER
Intervention: questionnary
Description: questionnaire in word format, sent by email and in paper version, which was established by the two main investigators (Diana Neponoceno, Pr Sophie-Myriam Dridi)

Intervention type: OTHER
Intervention: questionnary
Description: questionnaire in word format, sent by email and in paper version, which was established by the two main investigators (Diana Neponoceno, Pr Sophie-Myriam Dridi)

Intervention type: OTHER
Intervention: questionnary
Description: questionnaire in word format, sent by email and in paper version, which was established by the two main investigators (Diana Neponoceno, Pr Sophie-Myriam Dridi)

Intervention type: OTHER
Intervention: questionnary
Description: questionnaire in word format, sent by email and in paper version, which was established by the two main investigators (Diana Neponoceno, Pr Sophie-Myriam Dridi)
Study: NCT05758688

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT)
Description: The study intervention is Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) as part of the definitive treatment of gynecologic cancers in the post-hysterectomy, adjuvant setting. Patients will be treated with doses of 45 or 50.4 Gy in 1.8 Gy daily fractions. The volume treated will include the whole pelvis according to Radiation Therapy Oncology Group post-hysterectomy pelvis guidelines.
Study: NCT06440109

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emotional freedom technique (EFT)
Description: İntervention groups will be followed for six months and one of the six EFT therapies will be applied, one session every week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic touch (TD)
Description: İntervention groups will be followed for six months and one of the six TD therapies will be applied, one session every week.
Study: NCT06160778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: Intravenous ketorolac given at 0.5 mg/kg of body weight up to a maximum of 30 mg in a single dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Intravenous morphine given at 0.1 mg/kg of body weight up to a maximum of 5 mg in a single dose.
Study: NCT05750745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sensodyne Sensitivity & Gum
Description: Sensodyne Sensitivity \& Gum toothpaste is containing 0.454% w/w SnF2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crest Cavity Protection Fresh Lime
Description: Crest Cavity Protection Fresh Lime is containing 1150 parts per million (ppm) fluoride as Sodium fluoride (NaF).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sensodyne Repair and Protect
Description: Sensodyne Repair and Protect toothpaste is containing 5.0% w/w calcium sodium phosphosilicate (CSPS).
Study: NCT06546449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LH-001
Description: LH-001 will be administered oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LH-001
Description: LH-001 will be administered oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LH-001
Description: LH-001 will be administered oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LH-001
Description: LH-001 will be administered oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LH-001
Description: LH-001 will be administered oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LH-001
Description: LH-001 will be administered oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LH-001
Description: LH-001 will be administered oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered oral
Study: NCT06340126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active release techniques
Description: Active release techniques are soft tissue systems or movement-based techniques. It is used to treat muscles, nerves, fascia, ligaments, and tendons.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation exercises
Description: Relaxation exercises include breathing exercises, pelvic floor exercises, and postural exercises. Exercises will be done in a sitting position
Study: NCT04797000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag comes in 12.5 mg \& 25 mg tablets and is taken orally once per day (QD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comes in 12.5 mg \& 25 mg tablets and is taken orally once per day (QD)
Study: NCT06252675

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given intravenously (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Given Orally (PO)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Imaging
Description: Undergo regular care imaging/scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Blood and tissue samples

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClonoSeq Assay
Description: ClonoSEQ is an FDA-cleared, Clinical Laboratory Improvement Amendments of 1988 (CLIA)-validated measure used to determine minimal residual disease (MRD). This helps uncover how much, if any, cancer remains in your body during and after treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiration.
Study: NCT05585112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2%
Description: The child will be injected with lidocaine 2%,after that the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and pain after injection and treatment will be evaluated using the Wong-Baker faces pain rating scale

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine 4%
Description: The child will be injected with 4% Articaine, after that the treatment will be completed , Pain during injection and treatment will be assessed using the FLACC scale and Wong-Baker faces pain rating scale
Study: NCT06160778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline
Description: Intravenous normal saline placebo (labelled as morphine) given at 0.1 mg/kg of body weight up to a maximum of 5 mg in a single dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Intravenous normal saline placebo (labelled as ketorolac) given at 0.5 mg/kg of body weight up to a maximum of 30 mg in a single dose.
Study: NCT04859231

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Cow's milk-based formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational
Description: Cow's milk-based formula with added source of enriched whey protein
Study: NCT05803824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise therapy program
Description: patients will receive Baduanjin Qigong exercise plus selected exercise. the subjects will recive Baduanjin exercise 3 times each week, 30- 60 minutes each time for 12 weeks.~The whole set of Baduanjin exercise consists of 9 postures: (1) ready position, (2) holding the hands high with palms up. (3) posing like an archer shooting on left and right sides, (4) holding one arm aloft . (5) looking backwards to prevent sickness and strain, (6) swinging the head and lowering the body t. (7) moving the hands down the back and legs and touching the feet . (8) thrusting the fists and making the eyes glare . and (9) raising and lowering the heels .~Selected Exercise Program: Patients will receive~* balance exercises is composed of three phases, including warm-up, balance training and cool down.~* Resisted Exercises were given according to the standardized Oxford technique of progressive resistance exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise therapy program
Description: patients will receive Baduanjin Qigong exercise plus selected exercise. the subjects will recive Baduanjin exercise 3 times each week, 30- 60 minutes each time for 12 weeks.~The whole set of Baduanjin exercise consists of 9 postures: (1) ready position, (2) holding the hands high with palms up. (3) posing like an archer shooting on left and right sides, (4) holding one arm aloft . (5) looking backwards to prevent sickness and strain, (6) swinging the head and lowering the body t. (7) moving the hands down the back and legs and touching the feet . (8) thrusting the fists and making the eyes glare . and (9) raising and lowering the heels .~Selected Exercise Program: Patients will receive~* balance exercises is composed of three phases, including warm-up, balance training and cool down.~* Resisted Exercises were given according to the standardized Oxford technique of progressive resistance exercises
Study: NCT05764512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endorphin massage
Description: With the anterior surface of the fingertips of the hand, a V will be drawn slowly, starting from the sacral region and towards the ribs. The same process will be continued from the sacral region until the 7th cervical vertebra.~From the 7th cervical vertebra, the front surface of the fingertips will be descended first to the shoulders and then to the dorsal region of the upper and forearms in turn.~Starting from the dorsal region of the forearm, the first stage of the massage will end by descending to the upper arm, shoulders, 7th cervical vertebra, spine and sacral region with the back of the thumbs. These massage steps will be repeated until 20 minutes are completed.~Endorphin massage will be applied every 2 hours.
Study: NCT06038071

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutrition, IYCF, WASH education
Description: nutrition, IYCF, WASH education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutrition, IYCF, WASH education
Description: nutrition, IYCF, WASH education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutrition, IYCF, WASH education
Description: nutrition, IYCF, WASH education
Study: NCT05438160

Intervention type: DEVICE
Group type: OTHER
Intervention: Digital therapeutics app CT-155
Description: Patients to be treated with digital therapeutics app CT-155 downloadable into personal smartphones
Study: NCT06038071

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: scheduled anthropometric screening
Description: anthropometric screening by health care workers at 1, 3, and 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: family MUAC
Description: family MUAC training for the primary caregiver present at the time of recovery
Study: NCT05040243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yanqing Zhitong Ointment Acupoint application
Description: Yanqing Zhitong Ointment is a traditional external preparation of experiential prescription, which is an extract made by water extraction and concentration of Qingfengteng, Corydalis yanhusuo, Interleukin, Kansui, Asarum, etc. Clinical studies in the past ten years have preliminarily shown that it has the effects of warming meridians, promoting blood circulation, dredging collaterals and relieving pain, and has a definite effect.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: placebo acupoint application
Description: The control group was combined with placebo acupoint application on the basis of conventional acupuncture treatment.~Placebo patch: colored and drug-free patch (composition: petrolatum, food coloring) Acupuncture, application of acupuncture points and treatment course were the same as those in the treatment group.
Study: NCT05470660

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root coverage using coronally advanced flap combined with micro-needling
Description: modified coronally advanced flap will be performed in sites of recession defects, then micro-needling will be performed after 1 month from the coronally advanced flap procedure to ensure the initial flap healing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronally advanced flap combined with Alloderm
Description: modified coronally advanced flap will be performed in sites of recession defects in Association with alloderm to cover the exposed root and 3 mm of connective tissue mesial and distal to it.
Study: NCT05219721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T (CAR-GPRC5D)
Description: CAR-GPRC5D is an individualized, gene-modified autologous T cell immunotherapy product targeting GPRC5D that identifies and eliminates malignant and normal cells expressing GPRC5D. CAR specifically recognizes GPRC5D with a hypoimmunogenic human single-chain variable fragment (ScFv) that promotes car-T activation, proliferation, cytokine secretion and target cell killing through the CD3ζ domain. The amplification and persistence of CAR T are enhanced by 4-1BB costimulation signal.
Study: NCT04832841

Intervention type: DIAGNOSTIC_TEST
Intervention: anti-spike SARS-CoV-2 IgG
Description: Immunochemiluminescent assay by DiaSorin S.p.A. Italy

Intervention type: DIAGNOSTIC_TEST
Intervention: anti-spike SARS-CoV-2 IgG
Description: Immunochemiluminescent assay by DiaSorin S.p.A. Italy

Intervention type: DIAGNOSTIC_TEST
Intervention: anti-spike SARS-CoV-2 IgG
Description: Immunochemiluminescent assay by DiaSorin S.p.A. Italy
Study: NCT05876780

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SRP-9003
Description: Single IV infusion of SRP-9003
Study: NCT06551311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cycling training exercise
Description: Participants were randomly allocated to one of three groups: control (CTL), concentric cycling training (CON), or eccentric cycling training (ECC).~CTL: Received standard health education guidance.~CON and ECC: Participants in both the CON and ECC groups engaged in 24 exercise sessions, performed three times per week, lasting between 20 and 30 minutes. Both groups trained on a stationary bicycle, with the CON group performing concentric cycling and the ECC group performing eccentric cycling. The exercise intensity for both groups was set to a rating of perceived exertion (RPE) level of 13. Sessions began at 20 minutes and increased incrementally by 3-5 minutes each week until participants could sustain a 30-minute duration. The initial exercise intensity was set at 50% of the maximal output determined by a cardiopulmonary exercise test, and it was progressively increased by 5-10% of the estimated target power weekly, with adjustments made primarily to maintain an RPE of 13.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cycling training exercise
Description: Participants were randomly allocated to one of three groups: control (CTL), concentric cycling training (CON), or eccentric cycling training (ECC).~CTL: Received standard health education guidance.~CON and ECC: Participants in both the CON and ECC groups engaged in 24 exercise sessions, performed three times per week, lasting between 20 and 30 minutes. Both groups trained on a stationary bicycle, with the CON group performing concentric cycling and the ECC group performing eccentric cycling. The exercise intensity for both groups was set to a rating of perceived exertion (RPE) level of 13. Sessions began at 20 minutes and increased incrementally by 3-5 minutes each week until participants could sustain a 30-minute duration. The initial exercise intensity was set at 50% of the maximal output determined by a cardiopulmonary exercise test, and it was progressively increased by 5-10% of the estimated target power weekly, with adjustments made primarily to maintain an RPE of 13.
Study: NCT05025072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxycarbamide dispersible tablets
Description: Hydroxycarbamide dispersible tablets (20 x 50 mg)
Study: NCT06433570

Intervention type: GENETIC
Intervention: multiplex PCR
Description: Detection of Krupple Like Factor -1(KLF1/ EKLF) DNA Mutations in Beta Thalassemia Patients using multiplex PCR

Intervention type: GENETIC
Intervention: multiplex PCR
Description: Detection of Krupple Like Factor -1(KLF1/ EKLF) DNA Mutations in Beta Thalassemia Patients using multiplex PCR
Study: NCT05714839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab
Description: Belantamab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab and belantamab mafodotin
Description: Belantamab and belantamab mafodotin used in combination (delivered as separate drugs) will be administered.
Study: NCT04929379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: 145 mg oral fenofibrate daily for 76 weeks. Dosage is decreased to 48 mg daily if iGFR is or is estimated to be below 30 ml/min/1.73 m2.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive tablets identical to fenofibrate
Study: NCT04873817

Intervention type: DEVICE
Intervention: IonicRF Generator and compatible accessories
Description: Participants will receive IonicRF lesion generator, along with any country-specific market-released accessory (i.e. electrode, cannula, grounding pad, and adaptor cable) compatible with the IonicRF Generator
Study: NCT04973618

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APVO436
Description: APVO436~Dosage: APVO436 will be administered at a fixed dosage of 18 mcg after a weekly ramp up during Cycle 1 (Step-up dosing: C1D15: 6 mcg over 22 hours, C1D22: 12 mcg over 8 hours, C2D1: 18 mcg over 6 hours, C2D8: 18 mcg over 4 hours), totaling 18 µg in Cycle 1 and 72 µg/cycle for Cycles 2-4 for a total of 234 µg for the projected 4-cycle treatment course.~Dosage Form: IV Solutions for Intravenous Administration~Frequency: Weekly
Study: NCT04985383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AKST1210 S-15 at 250 mL/min
Description: Procedure: Hemodialysis, AKST1210 column size 150mL and blood-flow rate at 250mL/min

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AKST1210 S-15 at 450 mL/min
Description: Procedure: Hemodialysis, AKST1210 column size 150mL and blood-flow rate at 450mL/min

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AKST1210 S-25 at 250 mL/min
Description: Procedure: Hemodialysis, AKST1210 column size 250mL and blood-flow rate at 250mL/min
Study: NCT05419505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCH-aaes
Description: Administered by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antifibrinolytic Agent
Description: Self-administered by participants enrolled in Cohort 7.
Study: NCT06435325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Precision diet
Description: After the recruitment and randomization, the participants will follow the assigned diet and recommendations for 3-months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control diet
Description: After the recruitment and randomization, the participants will follow the assigned diet and recommendations for 3-months.
Study: NCT05560139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a-tDCS
Description: Transcranial direct current stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: a-tDCS
Description: Transcranial direct current stimulation
Study: NCT05780606

Intervention type: OTHER
Group type: OTHER
Intervention: Exposed to UV
Description: Two healthy volunteers will be exposed to UV or visible light in the forearm region. Suction bubbles, and skin biopsies will be performed in test areas, suction bubbles for transcriptome, biopsies for immunohistochemistry
Study: NCT04755244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evorpacept
Description: Fusion protein that blocks CD47-SIRPalpha pathway
Study: NCT04985383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AKST1210 S-25 at 450 mL/min
Description: Procedure: Hemodialysis, AKST1210 column size 250mL and blood-flow rate at 450mL/min
Study: NCT04755244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: BCL-2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Hypomethylating agent (HMA)
Study: NCT05352490

Intervention type: DIAGNOSTIC_TEST
Intervention: calculate LUS score
Description: calculate LUS score

Intervention type: DIAGNOSTIC_TEST
Intervention: calculate LUS score
Description: calculate LUS score
Study: NCT04985383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AKST1210 S-35 at 250 mL/min
Description: Procedure: Hemodialysis, AKST1210 column size 350mL and blood-flow rate at 250mL/min

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AKST1210 S-35 at 450 mL/min
Description: Procedure: Hemodialysis, AKST1210 column size 350mL and blood-flow rate at 450mL/min
Study: NCT05025072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide dispersible tablets
Description: Hydroxycarbamide dispersible tablets (20 x 50 mg)
Study: NCT06569420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug: Foritinib Succinate
Description: SAF-189s: 160 mg QD, 21 days a cycle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Crizotinib
Description: Crizotinib: 250 mg BID, 21 days a cycle